Ursula Matulonis
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ursula Matulonis as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 18:26 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04296890 · A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionImmunoGen, Inc. · completed · Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer · principal investigator
- Ph1/Ph2NCT02915523 · Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian CancerSyndax Pharmaceuticals · completed · Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer · principal investigator
- Ph2NCT02865811 · Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal CancerDana-Farber Cancer Institute · completed · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer · principal investigator
- Ph2NCT00856180 · Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian MalignanciesDana-Farber Cancer Institute · completed · Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer · principal investigator
- Ph2NCT00322881 · Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian CancerDana-Farber Cancer Institute · terminated · Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer · principal investigator
- Ph2NCT00275028 · AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI) · completed · Fallopian Tube Cancer, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Epithelial Cancer · principal investigator
- Ph2NCT00230542 · Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian CancerDana-Farber Cancer Institute · completed · Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 18:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Administrative CoreP01CA269021 · NCI · DANA-FARBER CANCER INST · fiscal years 2024 to 2026 · $191,557 awarded in 2026Same name and institution; not confirmed by an ID
- Program 02: Gynecologic CancersP30CA006516 · NCI · DANA-FARBER CANCER INST · fiscal years 2022 to 2026 · $42,618 awarded in 2026Same name and institution; not confirmed by an ID
- Evaluation of the Efficacy of Trametinib + Navitoclax in recurrent ovarian carcinomaP50CA240243 · NCI · DANA-FARBER CANCER INST · fiscal years 2020 to 2024 · $390,649 awarded in 2024Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Early Clinical Trials of New Anti-Cancer Agents with Phase I EmphasisU01CA062490 · NCI · DANA-FARBER CANCER INST · PI DONALD W. KUFE · fiscal years 1994 to 2013Named on NCT00275028
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 18:26 UTC. The ranking covers the 200 most relevant of 124 PubMed records, and a shared surname and initials can bring in a namesake. All 124 on PubMed
- 2,017 citationsRCR 64.0
- Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.N Engl J Med · 20121,491 citationsRCR 36.1
- 1,161 citationsRCR 32.0
- 1,121 citationsRCR 24.7
- Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.Ann Oncol · 2019717 citationsRCR 25.0
- Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.J Clin Oncol · 2007592 citationsRCR 13.3
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.Lancet Oncol · 2014480 citationsRCR 12.6
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.Lancet Oncol · 2019437 citationsRCR 14.6
- 386 citationsRCR 15.7
- 378 citationsRCR 9.4